Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Surgery Trials

Houston, Texas

Cancer surgery and procedure trials in Houston, TX

79 cancer surgery and procedure studies are recruiting participants at sites in Houston as of November 18, 2026, according to ClinicalTrials.gov. Cancer Surgery Trials can help you understand your options and connect with a study team.

Call (888) 350-9284
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Houston at a glance

  • 79 studies are recruiting at a site in Houston.
  • By phase: Phase 1 (8), Phase 1/2 (3), Phase 2 (21), Phase 3 (20), No phase (14), Observational (13). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (58), government (17), industry (4).
  • By research area: Breast Cancer (22), Lymphoma (20), Lung Cancer (15), Melanoma (8), Prostate Cancer (8), Pancreatic Cancer (6).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Houston

Basic details from each study's public record (the 30 most recently updated of 79). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UT MD Anderson Cancer Center
    Registry record
    NCT05111561 · updated
  2. Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

    • Phase 1
    • Ages 12 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UT MD Anderson Cancer Center
    Registry record
    NCT05372640 · updated
  3. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Lyndon Baines Johnson General Hospital · UT MD Anderson Cancer Center
    Registry record
    NCT05564377 · updated
  4. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Houston Methodist Hospital · Houston Methodist West Hospital · Methodist Willowbrook Hospital
    Registry record
    NCT07391774 · updated
  5. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center · Ben Taub General Hospital · UT MD Anderson - West Houston
    Registry record
    NCT06058377 · updated
  6. Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    M D Anderson Cancer Center
    Registry record
    NCT03941756 · updated
  7. Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    University of California, San Francisco
    Study site
    MD Anderson Cancer Center
    Registry record
    NCT05964504 · updated
  8. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    UT MD Anderson Cancer Center
    Registry record
    NCT05334069 · updated
  9. Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    M D Anderson Cancer Center
    Registry record
    NCT07407920 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Houston, TX on ClinicalTrials.gov.

Lung cancer studies recruiting in Houston

  1. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Houston Methodist Hospital · Houston Methodist West Hospital
    Registry record
    NCT04267848 · updated
  2. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Houston Methodist Hospital · Houston Methodist West Hospital · Methodist Willowbrook Hospital
    Registry record
    NCT04181060 · updated
  3. KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    The University of Texas MD Anderson Cancer Center ( Site 0009)
    Registry record
    NCT04165798 · updated
  4. Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    Michael E. DeBakey VA Medical Center, Houston, TX
    Registry record
    NCT02984761 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Houston, TX on ClinicalTrials.gov.

Prostate cancer studies recruiting in Houston

  1. Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UT MD Anderson Cancer Center
    Registry record
    NCT05691465 · updated
  2. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    NRG Oncology
    Study sites
    UT MD Anderson - West Houston · UT MD Anderson Cancer Center
    Registry record
    NCT05946213 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Houston, TX on ClinicalTrials.gov.

Lymphoma studies recruiting in Houston

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
    Registry record
    NCT06317662 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UT MD Anderson Cancer Center
    Registry record
    NCT06337318 · updated
  3. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study sites
    Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center · UT MD Anderson Cancer Center
    Registry record
    NCT04726241 · updated
  4. Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    M D Anderson Cancer Center
    Registry record
    NCT05011045 · updated
  5. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center · UT MD Anderson Cancer Center
    Registry record
    NCT04546399 · updated
  6. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center · UT MD Anderson Cancer Center
    Registry record
    NCT05675410 · updated
  7. A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    The University of Texas M D Anderson Cancer Center
    Registry record
    NCT05773040 · updated
  8. Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    MD Anderson Cancer Center
    Registry record
    NCT06218602 · updated
  9. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Houston Methodist Hospital
    Registry record
    NCT03150693 · updated
  10. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center · Ben Taub General Hospital
    Registry record
    NCT07215910 · updated
  11. Personalized NK Cell Therapy in CBT

    • Phase 2
    • Ages 15 to 80
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    M D Anderson Cancer Center
    Registry record
    NCT02727803 · updated
  12. Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center · Ben Taub General Hospital
    Registry record
    NCT05890352 · updated
  13. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
    Registry record
    NCT06124157 · updated
  14. Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Ohio State University Comprehensive Cancer Center
    Study site
    UT MD Anderson Cancer Center
    Registry record
    NCT07356245 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Houston, TX on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Houston

  1. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UT MD Anderson Cancer Center
    Registry record
    NCT05372614 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Houston, TX on ClinicalTrials.gov.

Ask about studies near Houston

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a surgery or another procedure, as each study is coded in the registry.

Cancer Surgery Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 350-9284

or send a short form

How should we reach you?

Call